ment was ineffective, as reflected by enlargement of the size of her goiter, worsening of the tenderness and dysphagia, and an increase in thyroid size on computed tomography scan. Subsequently, she was treated with two courses of cladribine, with initial response followed by progressive regrowth. The patient was then treated with pentostatin (2Ј-deoxycoformycin), a purine analog with adenosine deaminase inhibitory activity, at a dose of 4 mg/m 2 by intravenous infusion once every 2 weeks. The patient achieved a partial remission and continues to respond to this regimen 6 months (11 cycles) later, with ongoing shrinkage of her goiter (Fig 2B) .
LCH is most commonly a pediatric disease, but it can affect the adult population. It usually presents as a multisystem granulomatous infiltrate (in two thirds of cases) in adults. 1 Bone involvement predominates (80% of cases) with osteolytic and asymmetric lesions, 
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most often of the skull. Extraskeletal extension involves mainly the skin, the pituitary gland with diabetes insipidus, the liver and/or spleen, the lungs, and the orbits. 2 Thyroid gland infiltration remains uncommon with about 34 cases (22 adults and 12 children) reported in the medical literature, the vast majority presenting as multisystem disease. [3] [4] [5] [6] Due to its rarity, diagnosing LCH of the thyroid can be challenging. It can be clinically confused with the far more common benign goiters, undifferentiated carcinoma, lymphoma, lymphocytic thyroiditis, and chronic granulomatous thyroiditis. In fact, LCH of the thyroid can both masquerade as a malignancy or coexist with another thyroid neoplasm. LCH of the thyroid has been misdiagnosed as papillary carcinoma 7, 8 or anaplastic malignancy of the thyroid. 9 Papillary carcinoma can also coexist with LCH within the thyroid gland, 10 or within the lymph nodes draining the bed of a thyroid carcinoma. 5, 11, 12 The key to diagnosis of LCH is to identify the pathologic Langerhans cells that resemble the normal Langerhans cells of the skin, except they are not dendritic in morphology (Fig 3) . They do demonstrate a characteristic nuclear groove and positive immunostaining with CD68, S100, and CD1a. [4] [5] [6] The course of LCH is often unpredictable, varying from spontaneous regression to aggressive progression and death. It is not uncommon (20% of cases with multisystem involvement) to witness a capricious course with repeated recurrence of the disease and considerable risk of permanent sequelae.
13 Excluding LCH of the lung, which seems to be a separate syndrome, "multisystem" LCH disease has a worse prognosis than monofocal disease, with 10% to 30% mortality and a 50% risk of life-impairing morbidity. For aggressive disease, multiple chemotherapeutic regimens have been attempted: glucocorticoids, vinblastine, etoposide, cyclophosphamide, methotrexate, and doxorubicin. Recently, cladribine (2-CdA), a purine analog antimetabolite, has shown promising responses in LCH.
14 There are also anecdotal reports describing treatment of LCH with pentostatin (2-deoxycofomicin), another purine analog, which directly inhibits adenosine deaminase. 15 Thyroidectomy has also been used with some success. 3 Our patient demonstrated a 41% reduction in thyroid size after one course of cladribine, but the thyroid began to grow back with the second course. She was given pentostatin, which resulted in ongoing decrease in size after 11 courses and meeting criteria of partial remission with an overall 52% reduction in the size of the thyroid gland. 
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